Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 15/20 | 0.36 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.35 |
| ▸ | ECE1 | P42892 | 1/20 | 0.35 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.34 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.34 |
| ▸ | BRS3 | P32247 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL656768 | 0.93 | CTSA (0.38) | MMEAGTR1AGTR2 | |
| SCHEMBL656769 | 0.93 | CTSA (0.38) | MMEAGTR1AGTR2 | |
| SCHEMBL654760 | 0.91 | MME (0.37) | MMEAGTR1AGTR2 | |
| SCHEMBL654761 | 0.91 | MME (0.37) | MMEAGTR1AGTR2 | |
| SCHEMBL652532 | 0.90 | MME (0.40) | MMECTRB1AGTR1 | |
| SCHEMBL654096 | 0.90 | MME (0.35) | MMEAGTR1AGTR2 | |
| SCHEMBL654097 | 0.90 | MME (0.35) | MMEAGTR1AGTR2 | |
| SCHEMBL653054 | 0.89 | MME (0.35) | MMEAGTR1AGTR2 | |
| SCHEMBL653740 | 0.89 | MME (0.35) | MMEAGTR1AGTR2BRS3 | |
| SCHEMBL653741 | 0.89 | MME (0.35) | MMEAGTR1AGTR2BRS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009409-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009409-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | MME 10/4885CTRB1 249/4885ECE1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.